AVXL vs. APLS, AMRX, XENE, RARE, GMTX, CNTA, IMVT, TARS, CDTX, and MOR
Should you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include Apellis Pharmaceuticals (APLS), AMNEAL PHARMACEUTICALS (AMRX), Xenon Pharmaceuticals (XENE), Ultragenyx Pharmaceutical (RARE), Gemini Therapeutics (GMTX), Centessa Pharmaceuticals (CNTA), Immunovant (IMVT), Tarsus Pharmaceuticals (TARS), Cidara Therapeutics (CDTX), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry.
Anavex Life Sciences vs. Its Competitors
Anavex Life Sciences (NASDAQ:AVXL) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.
Anavex Life Sciences has a net margin of 0.00% compared to Apellis Pharmaceuticals' net margin of -30.24%. Anavex Life Sciences' return on equity of -45.67% beat Apellis Pharmaceuticals' return on equity.
Anavex Life Sciences presently has a consensus target price of $44.00, suggesting a potential upside of 388.35%. Apellis Pharmaceuticals has a consensus target price of $33.47, suggesting a potential upside of 37.65%. Given Anavex Life Sciences' higher possible upside, equities research analysts plainly believe Anavex Life Sciences is more favorable than Apellis Pharmaceuticals.
31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Apellis Pharmaceuticals had 17 more articles in the media than Anavex Life Sciences. MarketBeat recorded 18 mentions for Apellis Pharmaceuticals and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 0.65 beat Apellis Pharmaceuticals' score of 0.40 indicating that Anavex Life Sciences is being referred to more favorably in the media.
Anavex Life Sciences has higher earnings, but lower revenue than Apellis Pharmaceuticals. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Anavex Life Sciences has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.
Summary
Anavex Life Sciences and Apellis Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Anavex Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anavex Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:AVXL) was last updated on 10/17/2025 by MarketBeat.com Staff
